STOCK TITAN
  1. Home
  2. News
  3. ARQT

Arcutis Biotherapeutics, Inc. - ARQT STOCK NEWS

Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company based in Westlake Village, California, specializing in developing and commercializing treatments for dermatological diseases. Founded in 2016, Arcutis leverages recent advances in immunology and inflammation to create differentiated therapies targeting immune-mediated dermatological conditions.

Arcutis' lead product, ZORYVE (roflumilast) cream, is a topical treatment for plaque psoriasis and atopic dermatitis. The company has recently launched ZORYVE topical foam for seborrheic dermatitis and scalp psoriasis. Both formulations utilize roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor that has shown significant improvement in clinical trials.

Arcutis is also advancing its pipeline with ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema, and ARQ-255 for alopecia areata. The company champions meaningful innovation to address the urgent needs of patients living with chronic, immune-mediated skin conditions, aiming to improve treatment options and patient outcomes.

In recent developments, Arcutis has been actively participating in industry conferences, securing strategic collaborations, and expanding its workforce. The company's financial health is robust, with a strong cash position bolstered by a recent public offering and a strategic licensing agreement in Japan. Arcutis continues to focus on long-term growth and innovation, with multiple ongoing clinical programs targeting various inflammatory dermatological conditions.

For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.

News

Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia

Rhea-AI Summary
Arcutis Biotherapeutics, Inc. and Hangzhou Zhongmei Huadong Pharmaceutical Co have entered into a strategic collaboration and licensing agreement for the development, manufacture, and commercialization of topical roflumilast in Greater China and Southeast Asia. Huadong will receive an exclusive license for both the cream and foam formulations of topical roflumilast, and Arcutis will receive a $30 million upfront payment and potential milestone payments and royalties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
none
-
News

Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) achieved total revenues of $5.2 million in the second quarter of 2023, with net product revenues for ZORYVE® (roflumilast) cream 0.3% at $4.8 million, a 72% increase from the first quarter. The company reported a strong financial position with approximately $270 million in cash, cash equivalents, and marketable securities as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
earnings
-
News

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Arcutis Biotherapeutics, Inc. has granted 38,500 restricted stock units to five newly hired employees. The stock units will vest over four years, with 25% vesting on each annual anniversary of the vesting commencement date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
none
News

Arcutis to Report Second Quarter Financial Results

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
conferences earnings
-
News

Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark

Rhea-AI Summary
Arcutis Biotherapeutics announced that its ZORYVE cream for the treatment of plaque psoriasis is now covered as a preferred tier product on CVS Caremark's national commercial formularies, providing access to an additional 20 million commercial lives in the US. This brings the total number of commercially insured patients with access to ZORYVE to 131 million, representing 80% of covered lives in the US. The cream is a once-daily, steroid-free option that provides rapid results for both hard-to-treat and sensitive areas of the body.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.31%
Tags
none
-
News

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
none
News

Arcutis to Present at Upcoming Investor Conference

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.72%
Tags
conferences
-
News

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
none
-
News

Arcutis Announces Leadership Transition

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.79%
Tags
management
News

Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.83%
Tags
earnings

FAQ

What is the current stock price of Arcutis Biotherapeutics (ARQT)?

The current stock price of Arcutis Biotherapeutics (ARQT) is $14.99 as of December 20, 2024.

What is the market cap of Arcutis Biotherapeutics (ARQT)?

The market cap of Arcutis Biotherapeutics (ARQT) is approximately 1.8B.

What does Arcutis Biotherapeutics, Inc. specialize in?

Arcutis specializes in developing and commercializing treatments for dermatological diseases, focusing on immune-mediated conditions.

What are the main products of Arcutis Biotherapeutics?

Arcutis' main products include ZORYVE (roflumilast) cream for plaque psoriasis and atopic dermatitis, and ZORYVE topical foam for seborrheic dermatitis and scalp psoriasis.

Where is Arcutis Biotherapeutics headquartered?

Arcutis Biotherapeutics is headquartered in Westlake Village, California.

When was Arcutis Biotherapeutics founded?

Arcutis Biotherapeutics was founded in 2016.

What is ZORYVE?

ZORYVE is a brand name for Arcutis' roflumilast cream and topical foam, used to treat plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis.

What is the mechanism of action for ZORYVE?

ZORYVE utilizes roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor, which helps reduce inflammation by regulating immune response mediators.

What are Arcutis' latest achievements?

Recent achievements include the successful launch of ZORYVE foam, strategic licensing agreements, and strong financial results from a public offering.

How is Arcutis ensuring long-term growth?

Arcutis ensures long-term growth through continuous innovation, expanding clinical programs, strategic collaborations, and robust financial management.

What are some of Arcutis' ongoing projects?

Ongoing projects include clinical programs for ARQ-252 for hand eczema, ARQ-255 for alopecia areata, and additional studies for topical roflumilast formulations.

Where can I get more information about Arcutis Biotherapeutics?

For more information, visit Arcutis' official website at www.arcutis.com or follow them on LinkedIn, Facebook, Instagram, and X.

Stock ARQT logo
Arcutis Biotherapeutics, Inc.

Nasdaq:ARQT

ARQT Rankings

#2039 Ranked by Market Cap
N/A Ranked by Dividends

ARQT Stock Data

1.80B
103.96M
2.15%
113.6%
21.37%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WESTLAKE VILLAGE